SCHEMBL17554

SCHEMBL17554

O=C(OC(c1ccc(N2CCN(S(=O)(=O)c3cccs3)CC2)c(-c2ccccc2)c1)(C(F)(F)F)C(F)(F)F)C(F)(F)F

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GCKR Q14397 3/20 0.50
GCK P35557 1/20 0.50
PKM P14618 5/20 0.43
MAPT P10636 2/20 0.43
ALDH1A1 P00352 2/20 0.43
GAA P10253 1/20 0.43
TSHR P16473 1/20 0.43
GALR3 O60755 1/20 0.43
THRB P10828 1/20 0.42
JAK2 O60674 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HTT P42858 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPC1 O15118 1/20 0.40
USP2 O75604 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12078595 0.89 SMN1; SMN2 (0.47) GCKRGCKPKMMAPTALDH1A1
Trifluoroacetic Acid SCHEMBL17552 0.86 GCKR (0.62) GCKRGCKPKMGALR3
SCHEMBL17674 0.85 GCKR (0.66) GCKRGCKPKM
SCHEMBL12089572 0.81 GCK (0.52) GCKRGCKPKMMAPTALDH1A1
SCHEMBL22991 0.81 GCKR (0.47) GCKRGCKPKMMAPTALDH1A1
SCHEMBL17553 0.80 ALDH1A1 (0.36) GCKPKMMAPTALDH1A1GAA
SCHEMBL16361 0.78 GCKR (0.64) GCKRGCKPKMMAPTJAK2
Trifluoroacetic Acid SCHEMBL12078592 0.78 GCKR (0.54) GCKRGCKPKMMAPTALDH1A1
SCHEMBL17122 0.77 GCKR (0.62) GCKRGCKPKMALDH1A1MEN1
SCHEMBL17525 0.76 GCKR (0.61) GCKRGCKKMT2ANPC1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609081-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES Amgen Inc. (US) 2013-07-03 EP disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 GCKR 1/4885GCK 2/4885PKM 197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.